↓ Skip to main content

HPV6b virus like particles are potent immunogens without adjuvant in man

Overview of attention for article published in Vaccine, January 2000
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

patent
11 patents

Citations

dimensions_citation
140 Dimensions

Readers on

mendeley
55 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
HPV6b virus like particles are potent immunogens without adjuvant in man
Published in
Vaccine, January 2000
DOI 10.1016/s0264-410x(99)00351-5
Pubmed ID
Authors

Li Fang Zhang, Jian Zhou, Shao Chen, Lian Lian Cai, Qi Yu Bao, Fei Yun Zheng, Jie Qiang Lu, Jagadish Padmanabha, Kylie Hengst, Karen Malcolm, Ian H Frazer

Abstract

Subjects with genital warts were immunized three times or more with HPV6b VLPs without adjuvant. All immunized subjects had DTH to HPV6b L1 protein. Of 32 subjects, nine had HPV6b specific antibody prior to immunization and 22 acquired antibody with immunization. VLP specific antibody increased following a single immunization in 6 of 8 subjects with low level antibody at recruitment. Complete regression of genital warts was observed in 25 of 33 evaluable subjects over the 20-week observation period. We conclude that immunization with HPV6b L1 VLPs without adjuvant induces immunity to the L1 protein epitopes recognised during natural infection, and may accelerate regression of warts.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
Unknown 54 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 20%
Student > Ph. D. Student 9 16%
Student > Bachelor 6 11%
Student > Master 5 9%
Student > Doctoral Student 4 7%
Other 8 15%
Unknown 12 22%
Readers by discipline Count As %
Agricultural and Biological Sciences 13 24%
Medicine and Dentistry 7 13%
Biochemistry, Genetics and Molecular Biology 5 9%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Chemistry 3 5%
Other 5 9%
Unknown 18 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2018.
All research outputs
#5,446,994
of 25,374,917 outputs
Outputs from Vaccine
#5,006
of 16,509 outputs
Outputs of similar age
#10,949
of 109,733 outputs
Outputs of similar age from Vaccine
#15
of 75 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,509 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.7. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 109,733 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.